
Ristoglogene autogetemcel (risto-cel) - BLA If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel, risto-cel, to the FDA before X 1, 2027, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
74%
$0.00
6

74%
$0.00
6
6 markets tracked
No data available
| Market | Price |
|---|---|
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before April 2027) | 74% |
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before 2027) | 64% |
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before December) | 57% |
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before November) | 42% |
When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA? (before October) | 37% |